FR1601438A - - Google Patents

Info

Publication number
FR1601438A
FR1601438A FR170197A FR1601438DA FR1601438A FR 1601438 A FR1601438 A FR 1601438A FR 170197 A FR170197 A FR 170197A FR 1601438D A FR1601438D A FR 1601438DA FR 1601438 A FR1601438 A FR 1601438A
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR170197A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FR1601438A publication Critical patent/FR1601438A/fr
Expired legal-status Critical Current

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS, OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D11/00—Arrangement of elements for electric heating in or on furnaces
    • F27D11/08—Heating by electric discharge, e.g. arc discharge
    • C—CHEMISTRY; METALLURGY
    • C21—METALLURGY OF IRON
    • C21C—PROCESSING OF PIG-IRON, e.g. REFINING, MANUFACTURE OF WROUGHT-IRON OR STEEL; TREATMENT IN MOLTEN STATE OF FERROUS ALLOYS
    • C21C5/00—Manufacture of carbon-steel, e.g. plain mild steel, medium carbon steel or cast steel or stainless steel
    • C21C5/52—Manufacture of steel in electric furnaces
    • C21C5/5252—Manufacture of steel in electric furnaces in an electrically heated multi-chamber furnace, a combination of electric furnaces or an electric furnace arranged for associated working with a non electric furnace
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS, OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D11/00—Arrangement of elements for electric heating in or on furnaces
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS, OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D3/00—Charging; Discharging; Manipulation of charge
    • F27D3/18—Charging particulate material using a fluid carrier
FR170197A 1968-10-17 1968-10-17 Expired FR1601438A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR170197 1968-10-17

Publications (1)

Publication Number Publication Date
FR1601438A true FR1601438A (fr) 1970-08-24

Family

ID=8655735

Family Applications (1)

Application Number Title Priority Date Filing Date
FR170197A Expired FR1601438A (fr) 1968-10-17 1968-10-17

Country Status (10)

Country Link
US (1) US3610795A (fr)
JP (1) JPS4829422B1 (fr)
BE (1) BE739974A (fr)
BR (1) BR6913348D0 (fr)
DE (1) DE1952407B2 (fr)
ES (1) ES372628A1 (fr)
FR (1) FR1601438A (fr)
GB (1) GB1252310A (fr)
LU (1) LU59646A1 (fr)
SE (1) SE364311B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2220584A1 (fr) * 1973-03-05 1974-10-04 Siderurgie Fse Inst Rech

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891427A (en) * 1972-10-12 1975-06-24 Lectromelt Corp Method for melting prereduced ore and scrap
SE378735B (fr) * 1972-11-17 1975-09-08 Asea Ab
US3939297A (en) * 1973-12-07 1976-02-17 Chase Brass & Copper Co., Incorporated Stoker feed system
SE7503782L (sv) * 1975-04-02 1976-10-03 Asea Ab Sett och anordning for smeltreduktion av finkornigt jernoxidhaltigt material
DE2632707C3 (de) * 1976-07-21 1983-04-07 Ernst Dipl.-Ing. 4006 Erkrath Beiersdorf Beschickungsanlage an Elektro-Lichtbogenöfen zur Zugabe von Legierungsmitteln und Zuschlagstoffen
US4133967A (en) * 1977-06-24 1979-01-09 The United States Of America As Represented By The Secretary Of The Interior Two-stage electric arc - electroslag process and apparatus for continuous steelmaking
US4447906A (en) * 1981-02-02 1984-05-08 Lectromelt Corporation Arc furnace for producing aluminum
SE8303372L (sv) * 1983-06-14 1984-12-15 Asea Ab Ugnsanordning for smeltning av metaller eller metallegeringar
AT384669B (de) * 1986-03-17 1987-12-28 Voest Alpine Ag Anlage zur herstellung von stahl aus schrott
CA1311787C (fr) * 1986-06-24 1992-12-22 Masahisa Tate Four electrique pour la fabrication d'acier, a soufflage par la sole
FR2705767B1 (fr) * 1993-05-27 1995-07-21 Lorraine Laminage Procédé et installation de production d'acier liquide à partir de matières ferreuses riches en matières carbonées.
DE4339226A1 (de) * 1993-11-15 1995-05-18 Mannesmann Ag Verfahren und Vorrichtung zur Wertstoffgewinnung
AT404841B (de) * 1995-04-10 1999-03-25 Voest Alpine Ind Anlagen Anlage und verfahren zum herstellen von eisenschmelzen
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
ATE301273T1 (de) * 1999-05-18 2005-08-15 Danieli Technology Inc Elektrischer lichtbogenofen und verfahren zum kontinuierlichen chargieren
EP1702983A3 (fr) 2000-04-13 2007-01-10 Medical University of South Carolina Agents toxiques, ribozymes, ADNzymes et oligonucléotides antisens spécifiques des tissus et des pathogènes et procédé d'utilisation associé
AU2001278875B2 (en) * 2000-07-06 2007-06-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydrobenzothiazole analogues as neuroprotective agents
US6642002B2 (en) 2000-07-17 2003-11-04 Vanderbilt University Method of diagnosing pulmonary hypertension
EP2336166A1 (fr) 2000-10-12 2011-06-22 University Of Rochester Compositions inhibant la prolifération de cellules cancereuses
WO2002081710A1 (fr) * 2001-04-06 2002-10-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chromosomes artificiels pouvant servir de navette entre des cellules de bacterie, de levure et de mammifere
US7320959B2 (en) * 2001-10-01 2008-01-22 Vanderbilt University Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
AU2002332027A1 (en) * 2001-10-04 2003-04-14 The Government Of The United States Of America, As Tandem repeat markers
EP2311852A1 (fr) 2002-02-06 2011-04-20 Stasys Technologies, Inc. Molécules anti-infarctus
ATE549064T1 (de) 2002-06-14 2012-03-15 Us Gov Health & Human Serv Verfahren zur behandlung und prävention von kolitis, die il-13 und nk-t zellen betrifft
EP2116604A1 (fr) 2002-08-05 2009-11-11 University of Rochester Protéines chimères à domaine de transduction protéique/domaine désaminase, composés associés et utilisations correspondantes
ES2392511T3 (es) 2002-11-15 2012-12-11 Musc Foundation For Research Development Moduladores de complemento dianas sobre el receptor 2 de complemento
CA2507044A1 (fr) 2002-11-21 2004-06-10 Mary Lucero Modulation purinergique d'odeur
AU2005207002B2 (en) 2004-01-21 2011-03-17 University Of Utah Research Foundation Mutant sodium channel Nav1.7 and methods related thereto
WO2005086800A2 (fr) 2004-03-04 2005-09-22 Vanderbilt University Polypeptides socs pour inhiber la signalisation induite par la cytokine
WO2006016904A2 (fr) * 2004-04-14 2006-02-16 Uab Research Foundation Activateurs de la biosynthese de l'hexosamine en tant qu'inhibiteurs de lesion induite par l'ischemie ou le choc hemorragique
US20050244335A1 (en) * 2004-05-03 2005-11-03 Rinehart John J Methods and compositions related to increasing antitumor activity of chemotherapeutic agents
US20080269116A1 (en) 2004-05-11 2008-10-30 Taub Dennis D Methods of Inhibiting Proinflammatory Cytokine Expression Using Ghrelin
CA2564251C (fr) 2004-05-21 2018-04-10 The Uab Research Foundation Recepteurs de lymphocytes variables, polypeptides et acides nucleiques associes, et leurs utilisations
US20090118204A1 (en) * 2004-11-18 2009-05-07 University Of Rochester Methods and Compositions Related to Esculentoside A
JP5243040B2 (ja) 2004-12-21 2013-07-24 ムスク・ファウンデイション・フォー・リサーチ・ディベロップメント 創傷治癒および組織再生を促進するための組成物および方法
EP1877074B1 (fr) 2005-04-15 2013-03-27 The Government of the United States of America, as represented by the Secretary of Health and Human Services Traitement et prevention de la maladie intestinale inflammatoire agissant sur il-3 et sur les cellules nkt
US7919104B2 (en) 2005-05-19 2011-04-05 The United States Of America As Represented By The Department Of Health And Human Services, Centers For Disease Control And Prevention Functional epitopes of Streptococcus pneumoniae PsaA antigen and uses thereof
US8859585B2 (en) * 2005-05-25 2014-10-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Scopolamine for the treatment of depression and anxiety
PL2447356T3 (pl) 2005-06-07 2016-10-31 Mikroorganizmy eukariotyczne do wytwarzania lipidów i przeciwutleniaczy
WO2007047512A2 (fr) 2005-10-14 2007-04-26 Musc Foundation For Research Development Ciblage de pax2 en vue d'induire le traitement du cancer et l'immunite tumorale induite par defb1
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP1976985B1 (fr) 2005-12-29 2013-07-17 The Regents of the University of California Office of Technology Transfer Methodes et compositions associees au domaine kunitz mutant i de tfpi-2
TWI515007B (zh) 2006-01-05 2016-01-01 美國猶他大學研究基金會 改善以神經系統為標的之藥劑之性質之方法及組合物
WO2007092447A2 (fr) * 2006-02-06 2007-08-16 Burnham Institute For Medical Research Procedes et compositions lies au ciblage de tumeurs et de plaies
AU2007223427A1 (en) * 2006-03-01 2007-09-13 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
EP1996732A4 (fr) 2006-03-02 2010-03-31 Uab Research Foundation Détection, traitement de maladies mycobactériennes et découverte de médicaments
WO2008008720A2 (fr) 2006-07-10 2008-01-17 Synapsin Pharmaceuticals, Inc. Compositions et procédés se rapportant aux solénopsines et leur utilisation pour le traitement de troubles neurologiques et l'amélioration des performances physiques
CA2659574C (fr) 2006-08-02 2017-04-25 The Uab Research Foundation Procedes et compositions apparentes a des recepteurs de lymphocytes variables monoclonaux solubles d'une specificite antigenique definie
JP5926475B2 (ja) 2006-09-21 2016-05-25 ユニバーシティー オブ ロチェスター 筋緊張性ジストロフィーのためのタンパク質置換治療に関する組成物および方法
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
KR20090089462A (ko) 2006-12-11 2009-08-21 유니버시티 오브 유타 리써치 파운데이션 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
EP2101567A4 (fr) 2007-01-18 2010-04-21 Univ Utah Res Found Compositions et procédés pour détecter, traiter ou prévenir le stress réductif
US9381226B2 (en) 2007-02-08 2016-07-05 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
CN101801185A (zh) 2007-03-22 2010-08-11 耶鲁大学 与控制可变剪接的核糖开关有关的方法和组合物
EP2164329A4 (fr) 2007-05-08 2010-11-17 Burnham Inst Medical Research Inhibiteurs de la phosphatase alcaline non spécifiques à un tissu et leurs utilisations pour traiter une calcification vasculaire
EP2478766A3 (fr) 2007-05-09 2012-08-15 Burnham Institute for Medical Research Ciblage de protéinases hôtes en tant que stratégie thérapeutique contre des pathogènes viraux et bactériens
WO2008143676A1 (fr) 2007-05-23 2008-11-27 The Uab Research Foundation Neuraminidase pneumococcique détoxifiée et ses utilisations
EP2164996A4 (fr) 2007-05-29 2010-07-14 Univ Yale Riboregulateurs et procedes et composition pour l'utilisation de et avec des riboregulateurs
JP5552048B2 (ja) 2007-06-21 2014-07-16 ムスク ファンデーション フォー リサーチ ディベロップメント 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド
WO2009021163A2 (fr) * 2007-08-08 2009-02-12 University Of Rochester Augmentation de transfert génique
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
US20090053192A1 (en) * 2007-08-10 2009-02-26 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
CA2706317C (fr) 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions de doc1 et methodes de traitement du cancer.
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
AU2009281732A1 (en) * 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
EP2370080A1 (fr) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 en tant que cible thérapeutique dans les maladies cardiaques
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
WO2010132665A1 (fr) 2009-05-15 2010-11-18 Yale University Riborégulateurs gemm, conception, sur une base structurelle, d'un composé comprenant des riborégulateurs gemm et procédés et compositions utilisables avec des riborégulateurs gemm et permettant de les utiliser
WO2011020107A2 (fr) 2009-08-14 2011-02-17 Georgetown University Compositions et méthodes de dépistage et de traitement du cancer du sein
WO2011022502A1 (fr) 2009-08-18 2011-02-24 Georgetown University Compositions d'acide boronique et procédés se rapportant au cancer
WO2011031974A1 (fr) 2009-09-10 2011-03-17 Southern Research Institute Analogues d'acridine à utiliser dans le traitement de gliomes
EP2524042A2 (fr) 2010-01-12 2012-11-21 Yale University Motifs et composés arn structurés et leurs procédés d'utilisation
EP2544715A2 (fr) 2010-03-09 2013-01-16 Board Of Regents, University Of Texas System Procédés et compositions pour antigènes de chlamydia dans le diagnostic et le traitement d'infections et de maladies à chlamydia
US20110262347A1 (en) 2010-04-08 2011-10-27 The Salk Institute For Biological Studies Methods and compositions for enhanced delivery of compounds
US20130143955A1 (en) 2010-08-09 2013-06-06 Yale University Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
CA2858811A1 (fr) 2010-12-15 2012-06-12 Neuroadjuvants, Inc. Analogues de neuropeptides, compositions et procedes pour le traitement de la douleur
KR20140026410A (ko) 2011-03-15 2014-03-05 유니버시티 오브 유타 리서치 파운데이션 혈관 관련 황반병증 및 이의 증상을 진단 및 치료하는 방법
CA2868735C (fr) 2011-03-28 2020-02-25 University Of Utah Research Foundation Conjugues de peptide d renfemant une membrane localisant une molecule cargo ameliorant le potentiel en vue d'empecher l'entree du vih
US10766937B2 (en) 2011-09-06 2020-09-08 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
WO2014008475A2 (fr) 2012-07-05 2014-01-09 The Ohio State University Compositions et procédés associés à des vaccins viraux
WO2014141111A1 (fr) 2013-03-14 2014-09-18 Pluristem Ltd. Méthode permettant de prévenir et de traiter la maladie du greffon contre l'hôte
WO2014201118A2 (fr) 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions et méthodes de traitement ciblé de l'endométriose
PL3016512T3 (pl) 2013-07-05 2020-09-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rozpuszczalny CD33 do leczenia zespołów mielodysplastycznych (MDS)
WO2015143335A1 (fr) 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Méthodes et compositions pour protéines spike de coronavirus chimère
WO2016049380A1 (fr) 2014-09-24 2016-03-31 University Of Utah Research Foundation Mimétiques intermédiaires pré-épingle à cheveux du virus ebola et procédés d'utilisation
US10376549B2 (en) 2015-01-20 2019-08-13 Adcure Biotechnologies, Llc. Detargeted adenovirus variants and related methods
US10596247B2 (en) 2015-02-20 2020-03-24 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
US10765754B2 (en) 2015-08-28 2020-09-08 Navigen, Inc. Compositions and methods related to inhibition of respiratory syncytial virus entry
CN109069577B (zh) 2016-01-07 2022-08-19 纳维根公司 Hiv进入的d-肽抑制剂以及使用方法
US10751340B2 (en) 2016-06-06 2020-08-25 University Of Central Florida Research Foundation, Inc. Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions
AU2017301901A1 (en) 2016-07-29 2019-02-21 Ohio State Innovation Foundation Expression of pten-long with oncolytic viruses
JP7239179B2 (ja) 2016-10-05 2023-03-14 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド Ｎｋ細胞および抗ｐｄｌ１による癌治療法に関連する方法および組成物
WO2018176027A1 (fr) 2017-03-24 2018-09-27 Ohio State Innovation Foundation Nouveaux vecteurs viraux adéno-associés recombinés limitant la transduction hors cible dans le foie et leurs utilisations
US11684660B2 (en) 2017-03-28 2023-06-27 Ohio State Innovation Foundation Human PD1 peptide vaccines and uses thereof
US20230140818A1 (en) 2017-04-27 2023-05-04 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
EP3630144A4 (fr) 2017-05-25 2021-03-31 University of Central Florida Research Foundation, Inc. Nouveaux virus oncolytiques pour sensibiliser des cellules tumorales à la destruction par des cellules tueuses naturelles
WO2019067403A2 (fr) 2017-09-26 2019-04-04 Sanford Burnham Prebys Medical Discovery Institute Compositions et procédés d'évaluation de maladies démyélinisante et non démyélinisante douloureuses
US20210023219A1 (en) 2018-04-06 2021-01-28 North Carolina State University Cell assembly-mediated delivery of checkpoint inhibitors for cancer immunotherapy
WO2019217448A1 (fr) 2018-05-07 2019-11-14 Georgia State University Research Foundation, Inc. Compositions et procédés se rapportant à un extrait de rhamnus prinoides (gesho) pour l'inhibition de la formation de biofilm polymicrobien
US20210260187A1 (en) 2018-06-29 2021-08-26 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
WO2020051507A1 (fr) 2018-09-06 2020-03-12 The Broad Institute, Inc. Ensembles d'acides nucléiques destinés à être utilisés dans une administration ciblée
US11331269B2 (en) 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
US20210388389A1 (en) 2018-10-30 2021-12-16 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
WO2020161686A1 (fr) 2019-02-09 2020-08-13 King Abdullah University Of Science And Technology Compositions et méthodes diagnostiques et prognostiques du cancer
US11660330B2 (en) 2019-06-21 2023-05-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
JP2023554589A (ja) 2020-11-27 2023-12-28 ジェネラル ナノセラピューティクス エルエルシー 免疫媒介性疾患の治療のための方法及び組成物
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
WO2023173137A1 (fr) 2022-03-11 2023-09-14 Yale University Compositions et méthodes de modification génétique efficace et stable de cellules eucaryotes
WO2023220644A1 (fr) 2022-05-10 2023-11-16 Yale University Compositions et méthodes à base de queues ctla-4 synthétiques pour la reprogrammation de lymphocytes car-t et l'amélioration de l'efficacité anti-tumorale
KR20230167924A (ko) * 2022-06-03 2023-12-12 현대제철 주식회사 전기로
WO2024064824A2 (fr) 2022-09-21 2024-03-28 Yale University Compositions et procédés d'identification de cibles membranaires pour l'amélioration d'une thérapie par cellules nk

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US848422A (en) * 1905-06-23 1907-03-26 Frank Wynne Method of maintaining or increasing the fluidity of molten or semimolten materials by means of electricity.
US1339428A (en) * 1916-03-24 1920-05-11 Ludlum Electric Furnace Corp Method of operating an electric furnace

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2220584A1 (fr) * 1973-03-05 1974-10-04 Siderurgie Fse Inst Rech

Also Published As

Publication number Publication date
DE1952407A1 (de) 1970-08-20
SE364311B (fr) 1974-02-18
US3610795A (en) 1971-10-05
GB1252310A (fr) 1971-11-03
DE1952407B2 (de) 1971-03-11
LU59646A1 (fr) 1970-01-12
BE739974A (fr) 1970-03-16
BR6913348D0 (pt) 1973-01-02
JPS4829422B1 (fr) 1973-09-10
ES372628A1 (es) 1971-11-01

Similar Documents

Publication Publication Date Title
AU428130B2 (fr)
AU2374870A (fr)
AU5184069A (fr)
AU6168869A (fr)
AU6171569A (fr)
AU416157B2 (fr)
AU2581067A (fr)
AU2952567A (fr)
AU4811568A (fr)
AU421558B1 (fr)
AU3789668A (fr)
AU3224368A (fr)
AU4744468A (fr)
AU2580267A (fr)
AR203075Q (fr)
AU479393A (fr)
BE708888A (fr)
AU4503667A (fr)
AU4558658A (fr)
AU463027A (fr)
AU4270368A (fr)
BE726306A (fr)
AU479894A (fr)
AU4224469A (fr)
BE726876A (fr)

Legal Events

Date Code Title Description
ST Notification of lapse